- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
"Value" Decision by NICE Met With Disapproval
Both, the scientific community and a charitable organization, Prostate Cancer UK, have criticized the drug approval body for not offering abiraterone to sufferers until after chemotherapy.
The decision not to offer a life-extending drug to prostate cancer sufferers until after they have received chemotherapy is a "kick in the teeth" for patients, a charity has said.
Prostate Cancer UK said the drug could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects.
The charity said the National Institute for Health and Care Excellence's (Nice) decision was unjust.
Scientists have also expressed their disappointment over the health watchdog's guidance not to recommend the drug in this circumstance. Experts from the Institute of Cancer Research (ICR) said there was clear evidence abiraterone was beneficial for patients before they underwent chemotherapy.
In final draft guidance, Nice said that the drug should not be widely used in the NHS in England to treat prostate cancer patients whose cancer has spread and who have previously received another type of hormone therapy before they are given chemotherapy.
Read the report here: http://bit.ly/1t5K7Gc
Source: The Guardian
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
